5002012025-10-012025-12-315002012025-12-315002012025-04-012025-12-315002012025-10-012025-12-31in-capmkt:OtherExpenses1Member5002012025-10-012025-12-31in-capmkt:OtherExpenses2Member5002012025-10-012025-12-31in-capmkt:OtherExpenses3Member5002012025-04-012025-12-31in-capmkt:OtherExpenses1Member5002012025-04-012025-12-31in-capmkt:OtherExpenses2Member5002012025-04-012025-12-31in-capmkt:OtherExpenses3Member5002012025-10-012025-12-31in-capmkt:ReportableSegments1Member5002012025-10-012025-12-31in-capmkt:ReportableSegments2Member5002012025-10-012025-12-31in-capmkt:ReportableSegments3Member5002012025-10-012025-12-31in-capmkt:ReportableSegments4Member5002012025-04-012025-12-31in-capmkt:ReportableSegments1Member5002012025-04-012025-12-31in-capmkt:ReportableSegments2Member5002012025-04-012025-12-31in-capmkt:ReportableSegments3Member5002012025-04-012025-12-31in-capmkt:ReportableSegments4Member5002012025-10-012025-12-31in-capmkt:ReportableSegments1Member5002012025-10-012025-12-31in-capmkt:ReportableSegments2Member5002012025-10-012025-12-31in-capmkt:ReportableSegments3Member5002012025-10-012025-12-31in-capmkt:ReportableSegments4Member5002012025-04-012025-12-31in-capmkt:ReportableSegments1Member5002012025-04-012025-12-31in-capmkt:ReportableSegments2Member5002012025-04-012025-12-31in-capmkt:ReportableSegments3Member5002012025-04-012025-12-31in-capmkt:ReportableSegments4Member5002012025-10-012025-12-31in-capmkt:ReportableSegments1Member5002012025-12-31in-capmkt:ReportableSegments1Member5002012025-10-012025-12-31in-capmkt:ReportableSegments2Member5002012025-12-31in-capmkt:ReportableSegments2Member5002012025-10-012025-12-31in-capmkt:ReportableSegments3Member5002012025-12-31in-capmkt:ReportableSegments3Member5002012025-10-012025-12-31in-capmkt:ReportableSegments4Member5002012025-12-31in-capmkt:ReportableSegments4Member5002012025-10-012025-12-31in-capmkt:ReportableSegments1Member5002012025-12-31in-capmkt:ReportableSegments1Member5002012025-10-012025-12-31in-capmkt:ReportableSegments2Member5002012025-12-31in-capmkt:ReportableSegments2Member5002012025-10-012025-12-31in-capmkt:ReportableSegments3Member5002012025-12-31in-capmkt:ReportableSegments3Member5002012025-10-012025-12-31in-capmkt:ReportableSegments4Member5002012025-12-31in-capmkt:ReportableSegments4Member5002012025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15002012025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares500201INDIAGLYCONOTLISTEDINE560A01023INDIA GLYCOLS LIMITEDMain BoardEquity2025-04-012026-03-312026-02-102026-02-03INRCroresQuarterlyThird quarterMulti segment2026-02-1016:00:002026-02-1017:12:00Not applicable2025-10-012025-12-31UnauditedConsolidated2551100000074000002551840000059782000004084000005306000003523000004681000004122000001648680000024636600000881800000-8300000873500000129100000101300000230400000064310000000032600000675700000-25000006732000006732000000335100000510.7910.790010.7910.79Note on Financial Results: <BR> At point no.21: <BR> <BR> 'The Board of Directors of the Company at their meeting held on 16th October, 2025 had considered and approved the raising funds through issuance of up to of 51,03,765 Equity Shares, of face value of Rs. 5/- (Rupees Five) each, at a price of Rs. 915/- per Equity Share, (including a premium of Rs. 910/- per equity share), determined inaccordance with provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, for cash, for an aggregate amount of up to Rs. 4,66,99,44,975/- on preferential basis and the same has been approved by the Shareholders of the Company at their Extra Ordinary General Meeting held on 12th November, 2025. The Preferential Allotment Committee of the Board completed the allotment of the aforesaid equity shares to the respective allottee on 24th November, 2025 and the Company's paid up share capital was accordingly increased to Rs. 33,51,33,825/-. The Listing and Trading approvals from the Stock exchanges for above acquired equity shares were obtained on 5th Jnauary, 2026 effective from 6th January, 2026.' <BR> <BR> 'Face value of equity share capital' of Rs.5 is the Face value per equity share.' <BR> <BR> 2025-04-012025-12-31UnauditedConsolidated746662000004310000074709300000192777000001484300000-2116000009840000001407700000114150000048304300000723879000002321400000-83000002313100000302000000286700000588700000017244000000003344000002058800000-8200000205060000020506000000335100000532.8732.870032.8732.87Excise Duty14487000000Power and Fuel1057900000Other Expenses941900000Excise Duty42315600000Power and Fuel3128100000Other Expenses2860600000Bio-based Specialities and Performance Chemicals3130200000Potable Spirits17934600000Ennature Biopharma503400000Bio-Fuel3942800000Bio-based Specialities and Performance Chemicals9013400000Potable Spirits52563400000Ennature Biopharma1442800000Bio-Fuel116466000002551100000074666200000002551100000074666200000Bio-based Specialities and Performance Chemicals401800000Potable Spirits724300000Ennature Biopharma20400000Bio-Fuel329900000Bio-based Specialities and Performance Chemicals1041900000Potable Spirits2171500000Ennature Biopharma42200000Bio-Fuel850200000147640000041058000004681000001407700000102200000506000009061000002647500000Bio-based Specialities and Performance Chemicals33735600000Potable Spirits6147400000Ennature Biopharma4312100000Bio-Fuel1347880000057673900000480130000062475200000Bio-based Specialities and Performance Chemicals7201200000Potable Spirits3025500000Ennature Biopharma729900000Bio-Fuel744000000117006000002180490000033505500000Note1: Since there is no option to fill 'Exceptional Items' & 'Share of Profit and loss of JV' in the utility, the same is clubbed with 'Unallocated corporate expenses net of unallocable income'. <BR> <BR> Items that will not be reclassified to profit and loss-3200000-3200000Items that will not be reclassified to profit and loss-11200000-11200000-800000-2800000100000-200000-2500000-8200000